Bioxtreme

Bioxtreme operates at the intersection of medical devices, robotics, software, and clinical neurorehabilitation. Its focus is narrower than that of broad digital-health platforms: the company targets upper-extremity motor recovery for stroke, traumatic brain injury, and related neurological disorders. Its stated differentiation rests on Error Augmentation therapy, adaptive robotic forces, machine-learning-based personalization, and virtual 3D environments designed to encourage active motor learning rather than relying primarily on manual assistance. Dextreme 2.0 gives the company a defined product platform, while Plaxtreme broadens its named technology portfolio. Relative to generic physical-therapy software, Bioxtreme is more hardware- and clinically focused; relative to larger rehabilitation-device companies, its small 1–10 employee profile suggests a specialized, earlier-scale operating model.

Bioxtreme’s trajectory shows a long product-development period followed by more visible commercialization activity in 2026. Founded in 2010, the company has maintained a focused robotics-rehabilitation thesis centered on neurological recovery and lists four granted patents and four registered trademarks. The Apr 21, 2026 private equity investment from Serra Holding is the clearest capital inflection point, although no amount was disclosed and the company’s total funding cannot be calculated. The Jun 17, 2026 launch of Dextreme 2.0 represents a product inflection point, adding AI personalization, expanded content, assessment capabilities, and upgraded motors to the upper-limb rehabilitation platform. The appointment of Tamar Moyal as Sales Manager, with responsibility for North American and European sales operations, indicates an effort to build geographic reach beyond Israel. However, the available employee count remains in the 1–10 range, and there is no disclosed revenue, valuation, customer count, or follow-on financing. Growth therefore appears product- and market-development-led, but its scale is not yet measurable from public information.